Two-Thirds of Neurologists Expect to Start Some Patients on Aduhelm Next Year: Survey
From: McKnights Long Term Care News By: Alicia Lasek The outlook for the use of the drug is looking up, according to surveyor Spherix Global Insights. There are small increases in the number of Aduhelm prescribers and an uptick in patients for whom the therapy has been initiated. This is compared with flat activity seen in […]
Biogen’s Alzheimer’s Drug Aduhelm Slowly Gaining Steam Among Prescribing Neurologists, Study Finds
From: FiercePharma By: Noah Higgins-Dunn A week ago, Biogen CEO Michel Vounatsos sent the company’s shares into a nosedive after disclosing its launch of Alzheimer’s disease med Aduhelm was slower than expected. But according to one new analysis, there may be signs things are looking up. Data collected from a survey of 74 neurologists collected […]
Aduhelm Launch Trends Show Some Early Signs of Progress as the Biogen Team Aims to Moderate Near-Term Expectations
New research from Spherix’s Launch Dynamix™ service captures neurologists’ current perceptions and reported prescribing behavior for the first-to-market disease-modifying therapy for the treatment of Alzheimer’s disease EXTON, Pa., September 16, 2021/PRNewswire/ — The June 2021 approval of Biogen/Eisai’s Aduhelm fueled high initial expectations for the first-to-market disease-modifying therapy (DMT) for the treatment of Alzheimer’s disease. […]
Biohaven’s Ambitious Nurtec ODT Marketing Strategy Pays Dividends With Doctors in Migraine Market: Analyst
From: FiercePharma By: Beth Snyder Bulik Biohaven went all-in on marketing its added preventative indication for oral migraine med Nurtec. And now it’s reaping the rewards with doctors. Three months post-approval, 96% of neurologists were aware of the brand, while 65% are “highly familiar” with it, according to Spherix Global Insights’ postlaunch report…(read more)
Following the Recent Label Expansion, Biohaven’s Nurtec ODT Has Come Out Strong in the Migraine Prevention Market
Spherix Global Insights data show Nurtec ODT expanding its dominance of the CGRP class for migraine prevention with little anticipated share erosion for its closest competitors – Amgen’s Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality EXTON, Pa., September 9, 2021 /PRNewswire/ — In May 2021, the FDA approved the label expansion of Biohaven’s Nurtec ODT for the […]
Woodcock Calls for HHS OIG Investigation Into Aduhelm Approval
From: Policy & Medicine By: Thomas Sullivan As reported by Fierce Pharma, physicians are losing trust in the FDA due to the agency’s recent controversial approvals. Physicians’ trust in the agency is plummeting, according to a recent survey by Spherix Global Insights. More than 40% of the doctors surveyed said their confidence in the FDA has dropped over the […]
Early Sales of Biogen’s Alzheimer Drug Remain Unclear
From: Barron’s By: Josh Nathan-Kazis In a Wednesday note, Piper Sandler analyst Christopher Raymond cut his estimate for near-term sales, saying that an August survey of neurologists who treat Alzheimer’s disease showed a downward shift in their projections of Aduhelm’s use. The survey, conducted by the market research group Spherix Global Insights, polled 74 neurologists. The […]
J&J’s Ponvory May Be Late to the Multiple Sclerosis Market, but Doctors Still See Potential: Study
From: FiercePharma By: Beth Snyder Bulik Johnson & Johnson’s Ponvory is the fourth in its class and the ninth branded oral drug in multiple sclerosis, and it hasn’t exactly sped out of the starting gate. But it’s off to a surprisingly good start when it comes to physician opinions, a survey found. In a Spherix Global Insights survey, physicians projected a […]
‘Erratic’ FDA and Inconsistent Drug Decisions Put Doctors Off New Meds: Survey
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately—and doctors have had enough. Physicians’ trust in the agency is plummeting, according to a recent survey by Spherix Global Insights. More than 40% of the doctors surveyed said their confidence in […]
Specialty Physicians Weigh in with Opinions About the US Food and Drug Administration
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat, Ardelyx’s tenapanor, and the entire JAK inhibitor class EXTON, Pa., July 27, 2021 /PRNewswire/ — In reaction to major market events over the past several months, analysts at Spherix recently captured an increasingly negative sentiment towards the […]
